Biohaven (BHVN) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Biohaven (BHVN) over the past year, gaining 36.2% versus a loss of 29.9%. Pharvaris N.V. is the larger company by market cap ($2.18 billion vs $1.82 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | PHVS |
|---|---|---|
| Share price | $12.08 | $31.10 |
| Market cap | $1.82B | $2.18B |
| 1-day change | +1.26% | -0.06% |
| YTD return | +7.00% | +12.07% |
| 1-year return | -29.89% | +36.16% |
| 5-year return | — | +96.84% |
| EPS (TTM) | $-4.62 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-738.82M | $-25.99M |
| 52-week high | $18.57 | $43.25 |
| 52-week low | $7.48 | $20.65 |
| Distance from 52-week high | -34.93% | -28.09% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +76.08% | +84.47% |
| Average volume | 2.61M | 713.55K |
| Shares outstanding | 151.04M | 70.20M |
| Employees | 274 | 148 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed BHVN by 66.1 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
BHVN vs PHVS FAQ
Which is bigger, Biohaven or Pharvaris N.V.?
Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.18B compared with $1.82B for Biohaven (BHVN).
Which stock has performed better over the past year, BHVN or PHVS?
PHVS returned +36.16% over the past 12 months, compared with -29.89% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.